The antibody–drug conjugate DS-7300a, which targets B7-H3, has shown a significant decrease in tumor size in mouse models of castrate-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) [154]. The gene discussed is CD276; the disease is neoplasm.